Member Info for Latino

Linked in profile..ticks all the boxes:

Experienced leader in the healthcare diagnostic market with a passion for making the NHS better. Current member of the BIVDA executive board. Former Chair of the BIVDA procurement working party and member of the NHS supplier board. Always exploring ways to influence better patient outcomes, getting better value for money and supporting NHS Trusts to meet their goals. With a wide experience in procurement, supplier management, commercial management and operations - who has achieved growth, profitability, performance and engagement targets. Coming from a procurement background set in outsourcing for financial institutions, I have used my experience to help Roche and Beckman Coulter create and develop effective managed service solutions and capabilities.

Specialities : Executive Leadership, Strategic Planning, Outsourcing, Procurement, Supplier Management, Commercial Leadership, People Leader, Operational Management, Sales Management and Key Client Management.

Yep this guy appears to be the real deal…just check the CV. Best news here for a long time!

James Cheek - Wow new CEO has pedigree and extensive experience in dealing with NHS!

James brings extensive commercial and operational experience at a senior level through a successful career with established diagnostic companies such as Cepheid, Beckman Coulter, and Roche Diagnostics, as well as serving as an executive board member of the British In Vitro Diagnostics Association (BIVDA). The Board believes James' experience, especially his extensive involvement in selling into the NHS, will be valuable as the Company expands its commercial footprint and opportunities within the UK and more widely.

We are also pleased to announce the appointment of Dr Gino Miele, Chief Scientific Officer at genedrive, to the Board as an Executive Director, with immediate effect. Gino has considerable experience in the development of molecular diagnostic technologies and systems and has been the R&D Director at genedrive since 2015 and its predecessor Epistem since 2011. Prior to that Gino has held associate director positions in personalised medicine at Wyeth and Pfizer. Gino has been a key driver in the development of the genedrive(R) system and the recent menu of pharmacogenetic tests.

Finally…best news here!

On the charts…

Cannot believe how such a highly credible BoD (CV) failing investors here.

Brad needs to smell the coffee here or walk out. What on earth is he playing at! Needs to start delivering now and fast. Behaving like an amateur CEO…as he got what it takes? Really starting to question now..

Well you’ll have to swallow your pride pill…cos you’re wrong so far and the market is proving this…SP now 2.35p

What you’re saying is everybody buying is stupid and dumb and you know better…!

‘Nobody’…lol there are many grabbing with a barge pole! Need to review your investment acumen..

Also worth noting….

During the course of its due diligence, the Potential Equity Investor has advised that it can, where suitable, introduce companies in which it has an equity interest to AMTE Power with the view to generating offtake agreements for sodium-ion battery cells. It would also provide similar introductions to other companies with which it has strategic relationships, where battery technology is currently being deployed at large scale in various industries, for example in renewable energy.

Given the potential for revenue growth that, in the Directors' view, can be realised through these arrangements, AMTE Power intends to issue the Potential Equity Investor with compensatory warrants in recognition of the value of such offtake agreements. If required, shareholder approval for the issue of any such warrants will be sought in due course.

The board of directors of the Company has been informed by the Potential Equity Investor that its due diligence is progressing; that significant strategic work has been undertaken; that further confirmatory and technical due diligence is its current focus; and that this work is now anticipated to complete by the end of October 2023.

See you’re retracting your earlier statement from 2.5p to possibly 3p now lol…why make such predictions just let it be!

Good find…Strategic investor is also offering…

AMTE added that this new investor has offered, where suitable, to introduce companies in which it has an equity interest for possible sodium-ion battery cell offtake deals and other large-scale projects.

At least shareholders can’t complain here, ample time to get out at strategic investor very clear and honoured the 1.7p. A strategic investor so shown some class there by at least being upfront..

At least they now have a strategic investor here..can help this company move forward.

Peanuts, diamond news can come any time and surely now imminent news due gla

…and very possibly 7am RNS tomorrow of Contract with major would be cunning!

Just gone thru…gla

Well don’t need any placing, they have EGHOS funds. Only if they want to pay stop EGHOS drawdown and end facility..some £2m still available for drawdown!

All time low, prospectus done. Turnaround will now start. Buying more!

Results were very fishy, and if the guys inside are shocked and surprised then there is something wrong somewhere hence why investigating results….could well be some big errors or other but need to wait for analysis.

Dr. Daniil Nemenov, SVP for Clinical Development and Operations of Ovoca Bio plc, said: "We are surprised and disappointed that the Study did not have a positive conclusion regarding the superiority of Orenetide versus placebo. The Company now intends to analyse the results from the Study in further detail, including investigating the reasons for potential differences between the Study results and results from previously conducted clinical trials of Orenetide. While we are naturally disappointed with these results, I would like thank all those involved in the Study to date, including the patients who were enrolled, their families, our investigators, staff, and all of the dedicated Ovoca employees."